We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA Issues Revised Guidance on Biomarkers, Diagnostic Criteria for Alzheimer’s Medicines
EMA Issues Revised Guidance on Biomarkers, Diagnostic Criteria for Alzheimer’s Medicines
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a revised guideline on the clinical investigation of medicines for the treatment of Alzheimer’s disease, focusing on the design and analysis of safety studies and the potential use of biomarkers in various stages of medicinal development.